Alembic Pharmaceuticals LimitedNSE: APLLTD

Press Release Dec 04 2024

· Issued by Alembic Pharmaceuticals Limited

Filed with NSE ·

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 04, 2024, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)".

View Attachment

6ix hasn’t read this filing yet.

Alembic Pharmaceuticals Limited on 6ix

Earlier from Alembic Pharmaceuticals

Later from Alembic Pharmaceuticals

All Alembic Pharmaceuticals news releases